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To identify changes in proteins accompanying transformation of normal lung epithelial
cells  to cancer cells, we performed a comparative proteomic study using two cell lines
representing  matching normal and cancer cells. Strikingly, a good number of detected
actin  cytoskeletal proteins were preferentially downregulated in cancer cells, while simi-
lar  numbers of proteins in other organelles were up or downregulated. We  also found that
the formation of stress ﬁbers and focal adhesions were substantially decreased in can-
cer  cells. Protein network analysis showed that the altered proteins are highly connected.
These  results provide novel insights into the molecular mechanism promoting lung cancer
TRAQ
roteomic
ung cancer
progression.
©  2014 The Authors. Published by Elsevier B.V. on behalf of European Proteomics
Association  (EuPA). Open access under CC BY-NC-ND license.
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.  Introduction
ung cancer is the leading cause of cancer-related mortality
n  the US and worldwide, and about 85% of the cases are non-
mall-cell  lung cancer (NSCLC) [1,2]. Using established cancer
ell  lines has been very powerful in identifying molecular
echanisms underlying tumorigenesis. Notably, recent work
as established a very useful pair of lung cell lines [3,4] that
an  be used to identify changes accompanying the transfor-
ation  of molecular changes underlying the transformation
f  normal cells to malignant cells. They are the HBEC30KT
∗ Corresponding author. Tel.: +1 972 883 5757; fax: +1 972 883 5759.
E-mail  address: li.zhang@utdallas.edu (L. Zhang).
1 These authors contributed to this work equally.
2 Present address: Max-Planck-Institute for Neurological Research, c/
212-9685 ©  2014 The Authors. Published by Elsevier B.V. on behalf of E
ttp://dx.doi.org/10.1016/j.euprot.2014.01.001and HCC4017 cell lines [3,4]. The HCC4017 cell line represents
non-small-cell lung cancer (NSCLC) cells isolated from a can-
cer  patient, while the HBEC30KT cell line represents the
normal,  nonmalignant bronchial epithelial cells developed
from  the same patient. Thus, this pair of cell lines provides
a  good model for identifying changes associated with cancer,
not  merely variations among different persons.
The advent of proteomic technologies has made it possi-o DESY, Notkestrasse 85, 22607 Hamburg, Germany.
ble  to systematically identify and characterize the alterations
in  proteins in cells undergoing various physiological and
pathophysiological changes. Particularly, the isobaric tags for
relative and absolute quantitation (iTRAQ) proﬁling technol-
uropean Proteomics Association (EuPA). Open access under CC BY-NC-ND license.
 o m i c2  e u  p a o p e n p r o t e
ogy enables the quantitative and direct comparison of the
levels  of a large number of proteins in two or more  samples
[5,6].  The iTRAQ technology employs isobaric tags with the
same  total mass but different reporter group mass to label pep-
tides,  which are then detected by MS/MS  mass spectrometry.
iTRAQ can simultaneously identify and quantify the levels of
over  1000 proteins in 2–8 samples [7]. iTRAQ provides a pow-
erful  method for identifying differentially expressed proteins
[5].  Thus, we  decided to apply the iTRAQ technology to identify
the  protein changes accompanying lung epithelial cells when
they  become malignant.
Using  iTRAQ, we  were  able to consistently identify and
detect  the levels of over 1500 proteins in lung cells. Among
them,  the levels of over 100 proteins exhibited statistically sig-
niﬁcant differences in cancer cells, when compared to normal
cells.  Particularly, the levels of 36 proteins actively involved
in  the function of actin cytoskeleton and cell motility were
selectively downregulated in cancer cells. Further GO analy-
sis  identiﬁed signiﬁcant changes in the levels of a group of
nuclear  regulatory proteins in cancer cells. Network analysis
suggested  that certain regulatory proteins may  play an impor-
tant  role in mediating the changes in proteins in other cellular
compartments, such as those involved in actin cytoskele-
ton.  These results show that proteomic analysis can identify
important  molecular changes underlying cancer cell progres-
sion.
2.  Materials  and  methods
2.1.  Lung  cell  line  maintenance  and  preparation  of
protein  extracts
HBEC30KT and HCC4017 cell lines representing normal and
NSCLC  cells [3,4] were  provided by Dr. John Minna’s lab (UTSW)
as  a gift. They were  developed from the same patient and
were  maintained in ACL4 supplemented with 2% FBS under
5%  CO2 at 37 ◦C. ‘HBEC30KT and HCC4017’ cells were collected
and  lysed by using the RIPA buffer (Cell Signaling Technol-
ogy)  containing the protease inhibitor cocktail (Invitrogen) and
phosphatase  inhibitors. Protein concentrations were deter-
mined  by using the BCA assay kit (Thermo Scientiﬁc).
2.2.  Protein  isobaric  labeling  with  iTRAQ  reagents
Proteins from HBEC30KT and HCC4017 cell lines were
extracted, and protein concentration was  detected, as
described  below for Western blotting analysis. Isobaric label-
ing  was  carried out as described [8] and according to the
procedure recommended by the PennState Hershey Col-
lege  of Medicine Mass Spectrometry Core facility (http://med.
psu.edu/web/core/proteinsmassspectometry/protocols/itraq).
Brieﬂy, 100 g of proteins from each sample was  reduced with
5  mM TCEP (tris-(2-carboxyethyl) phosphine) at 60 ◦C for 1 h.
Cysteine  residues were  blocked with 18 mM iodoacetamide
at  room temperature for 30 min. Then, the proteins were
precipitated with ice-cold acetone (90%, v/v) overnight at
−20 ◦C and centrifuged. The protein pellets were  washed with
ice-cold  90% acetone and 20 mM TEAB (triethylammoniumbi-
carbonate) and air-dried. Protein pellets were  then suspended s 3 ( 2 0 1 4 ) 1–12
in  buffer containing 0.5 M TEAB–0.1% SDS, at a concentration
of  5 mg/ml, and then digested with trypsin at 40 ◦C overnight.
Isobaric labeling reagents were purchased from Applied
Biosystems. 8plex isobaric labeling kit containing tags with
a  reporter mass ranging from 113 to 121 was  used. Isobaric
tagging iTRAQ reagent in isopropanol was added directly
to  the protein digest to reach a ﬁnal concentration of 61%
isopropanol. The mixture was  incubated at room temperature
for  2 h. The reaction was  then quenched by addition of 100 l
of  water. The eight labeled peptide pools were  mixed together
and  lyophilized.
2.3.  Mass  spectrometry
The iTRAQ protein samples were  analyzed by the PennState
Hershey College of Medicine Mass Spectrometry Core facil-
ity.  Prior to MS analysis, protein samples were  fractionated
and separated into 15 fractions by using 2D-LC. SCX Sepa-
rations  were performed on a passivated Waters 600E HPLC
system,  using a 4.6 mm × 250 mm PolySULFOETHYL Aspar-
tamide  column (PolyLC, Columbia, MD), at a ﬂow rate of
1  ml/min. Buffer A contained 10 mM ammonium formate, pH
2.7,  in 20% acetonitrile/80% water. Buffer B contained 666 mM
ammonium  formate, pH 2.7, in 20% acetonitrile/80% water.
The  gradient was Buffer A at 100% (0–22 min  following sample
injection), 0%→40% Buffer B (16–48 min), 40%→100% Buffer B
(48–49 min), then isocratic 100% Buffer B (49–56 min), then at
56  min  switched back to 100% Buffer A to re-equilibrate for the
next  injection. The ﬁrst 26 ml  of eluant (containing all ﬂow-
through  fractions) was  combined into one fraction, then 14
additional  2-ml fractions were  collected. All 15 of these SCX
fractions  were  dried down completely to reduce volume and
to  remove the volatile ammonium formate salts, then resus-
pended  in 9 l of 2% (v/v) acetonitrile, 0.1% (v/v) triﬂuoroacetic
acid and ﬁltered prior to reverse phase C18 nanoﬂow-LC sepa-
ration.  The fractionation was  performed to purify the peptides
and  increase the sensitivity of MS. Information from all frac-
tions  were combined and analyzed as a whole in the end.
For  2nd dimension separation by reverse phase nanoﬂow
LC,  each SCX fraction was autoinjected onto a Chromolith
CapRod column (150 mm × 0.1 mm,  Merck) using a 5 l injector
loop  on a Tempo LC MALDI Spotting system (ABI-MDS/Sciex).
Buffer C was  2% acetonitrile, 0.1% triﬂuoroacetic acid, and
Buffer  D was  98% acetonitrile, 0.1% triﬂuoroacetic acid. The
elution  gradient was  95% C/5% D (2 l/min ﬂow rate from
0  to 3 min, then 2.5 l/min from 3 to 8.1 min), 5% D→38%
D  (8.1–40 min), 38% D→80% D (41–44 min), 80% D→5% D
(44–49  min) (initial conditions). Flow rate was 2.5 l/min during
the  gradient, and an equal ﬂow of MALDI matrix solution was
added  post-column (7 mg/ml  recrystallized CHCA (a-cyano-
hydroxycinnamic acid), 2 mg/ml  ammonium phosphate, 0.1%
triﬂuoroacetic acid, 80% acetonitrile).
After sample spot drying above, thirteen calibrant spots
(ABI  4700 Mix) were added to each plate manually. MALDI
target  plates (15 per experiment) were analyzed in a
data-dependent manner on an ABI 5800 MALDI TOF-TOFs.
MS/MS spectra were taken by using up to 2500 laser shots
per  spectrum at Laser Power 3000, with CID gas Air at
1.2–1.3  × 10−6 Torr. As each plate was entered into the instru-
ment, a plate calibration/MS Default calibration update was
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erformed, and then the MS/MS  default calibration was
pdated. MS  spectra were then acquired from each sample
pot  using the newly  updated default calibration, using 500
aser  shots per spot, laser intensity 3200. A plate-wide inter-
retation  was  then automatically performed, choosing the
ighest  peak of each observed m/z value for subsequent
S/MS  analysis.
Up  to 2500 laser shots at laser power 4200 were  accumu-
ated for each MS/MS  spectrum. When the MS and MS/MS
pectra  from all 15 plates in a sample set had been acquired,
rotein identiﬁcation and quantitation were  performed using
he  Paragon algorithm as implemented in Protein Pilot 4.0
oftware,  searching the spectra against either species-speciﬁc
ubsets (plus common contaminants) of the NCBInr database
oncatenated with a reversed “decoy” version of itself, or the
ntire  NCBInr database. For ProteinPilot analyses, the preset
horough  Search settings were  used, and identiﬁcations must
ave  a ProteinPilot Unused Score > 1.3 (>95% Conﬁdence inter-
al)  in order to be accepted. In addition, the only protein IDs
ccepted  must have a “Local False Discovery Rate” estimation
f  no higher than 5%, as calculated from the slope of the accu-
ulated  Decoy database hits by the PSPEP (Proteomics System
erformance  Evaluation Pipeline) program by Sean Seymour
nd  colleagues [9]. Note that this Local or “Instantaneous” FDR
stimate is much  more  stringent than p < 0.05 or 95% conﬁ-
ence  scores in Mascot, Sequest, ProteinPilot, or the aggregate
alse  Discovery Rate estimations (2 × number of Decoy
atabase IDs/Total IDs at any chosen threshold score) com-
only  used in the literature, and combined with the ProGroup
lgorithm included in ProteinPilot gives a very conservative
nd  fully MIAPE-compliant list of proteins identiﬁed. The total
uman  sequences searched contain 30345 Protein Sequences,
lus  360 common lab contaminants. The Local False Discovery
ate  (FDR) for the lowest ranking accepted protein ID was less
han  5% with the p-value between <0.01 and <0.001.
.4.  Mass  spectrometry  data  analysis
plex iTRAQ MS/MS  analysis was  performed twice, with each
et  having 4 normal and 4 cancer cell samples. Therefore,
e  gained 4 sets of iTRAQ data for each experiment. From
wo  experiments, we gained 8 sets of protein ratios com-
aring  cancer cell line (HCC4017) with the normal cell line
HBEC30KT). Only those proteins that were identiﬁed in at
east  four experiments were  considered as detected. Data from
ach experiment were  normalized, and estimated changes in
he relative amounts of each identiﬁed protein (i.e., cancer vs.
ormal cells) calculated. Each of the peptides identiﬁed from
 speciﬁc protein is presented as a ratio, with a ratio of 1.0 rep-
esenting  no signiﬁcant change. The mean and median ratios
or  each identiﬁed proteins were calculated in MS  Excel. Pro-
eins  that showed ratios higher than 1 in all detected samples
nd  had mean and median ratios of at least 1.3 were  con-
idered  to be upregulated, while proteins that showed ratios
ess  than 1 in all detected samples and had mean and median
atios  of less than 0.76 were considered to be downregulated.
he selected up- or downregulated proteins are listed in sup-
lementary  Tables S2 and S3. The statistical signiﬁcance of
ltered  proteins was  further conﬁrmed by using p values. The
 values were  calculated based on Fisher’s method [10]. For all s 3 ( 2 0 1 4 ) 1–12 3
p-values pi from n replicates, x = −2 ×
∑
[ln(pi)] was  calculated,
which follows Chi-square distribution with degree of freedom
2n,  to obtain the combinational p-value for one protein. Those
with  p values <0.05 are listed in Tables 2–5.
Gene Ontology (GO) analysis of identiﬁed proteins and up
or  downregulated proteins in cancer cells was  performed by
the  NIH DAVID application. Protein interaction networks were
constructed  by using Pathway Studio version 7 and by  using
the  GENEMANIA program.
2.5.  Western  blotting  analysis
About 50 g proteins from the cells were  electrophoresed
on 9% SDS-polyacrylamide gels, and then transferred onto
the  Immuno-Blot PVDF Membrane (Bio-Rad). The membranes
were  probed with the desired antibodies, followed by detec-
tion  with a chemiluminescence Western blotting kit (Roche
Diagnostics). The signals were  detected by using a Carestream
image  station 4000MM Pro, and quantitation was performed
by  using the Carestream molecular imaging software version
5.0.5.30  (Carestream Health Inc.). Polyclonal anti-utrophin,
anti-transgelin, and anti-NAMPT antibodies were purchased
from  Santa Cruz Biotechnology. Monoclonal anti-phospho-
EphA2 (Ser897), anti-EphA2 and anti--actin antibodies were
purchased  from Cell Signaling Technology.
2.6.  Immunoﬂuorescence  microscopy
For immunoﬂuorescence microscopy, cells were  grown on
polylysine-coated slides and were ﬁxed with 4% formalde-
hyde.  Cells were washed two times with PBS containing 0.2%
BSA  and then permeabilized with 0.1% Triton X-100 contain-
ing  0.2% BSA. Immunoﬂuorescence staining was  performed
as  described [11]. Fluorescent images were acquired by using
a  multi-channel Zeiss Axio Observer.Z1 ﬂuorescent micro-
scope  with a Zeiss 40× Oil immersion lens and with a high
speed  AxioCam MRm Rev3 monochrome camera. The soft-
ware  used was Carl Zeiss AxioVision Rel 4.8.1, set to the
multi-dimensional mode that allows automatic ﬁlter changes
and  image  capturing. Vinculin was stained with monoclonal
anti-vinculin antibody (Sigma V9131). The secondary anti-
body  used was FITC-conjugated goat anti-mouse antibody
(Invitrogen A11017). F-actin was  visualized with Alexa Fluor
568-phalloidin (Invitrogen A12380).
3.  Results
3.1.  iTRAQ  detected  over  1500  proteins  in  normal  and
lung  cancer  cells
We  extracted proteins from both the normal, non-malignant
bronchial epithelial cell line HBEC30KT and the NSCLC line
HCC4017  [3,4]. We  performed iTRAQ analysis of the proteins
and  obtained the ratios of proteins in cancer vs. normal cells
in  eight biological replicates (see Section 2 and supplementary
Table S1). In total, we  detected 1584 proteins with high statis-
tical  conﬁdence (Table 1). The Local False Discovery Rate (FDR)
for  the lowest ranking accepted protein ID was  less than 5%
with  the p-value between <0.01 and <0.001. The ratios from the
4  e u  p a o p e n p r o t e o m i c s 3 ( 2 0 1 4 ) 1–12
Table 1 – Summary of the proteins identiﬁed in HCC.
Total Nuc Cyto-s Cyto-p Mito ER Act
Detected 1584 532 392 1182 241 192 118
Up 183 (53) 72 (17) 34 (14) 121 (38) 18 (5) 24 (8) 1 (1)
Down 275 (86) 52 (17) 51 (14) 204 (69) 34 (7) 19 (6) 81 (36)
ted by fold changes. The numbers in the parenthesis represent those with
 mitochondria; ER, endoplasmic reticulum; Act, actin cytoskeleton.
Fig. 1 – Western blotting analysis of selected proteins in
normal  and cancer lung cells. The normal HBEC30KT lung
epithelial  (HBEC) and NSCLC HCC4017 (HCC) cells were
cultured, and proteins were extracted. Protein levels were
detected  by using Western blotting. (A) The levels of
nicotinamide phosphoribosyltransferase (NAMPT) and
transgelin  (TAGLN) in normal and NSCLC cells. (B) The
levels  of utrophin (UTRN) in normal and NSCLC cells. (C)
The  levels of total and phosphorylated EphA2 receptor in
normal  and NSCLC cells. The protein level of -actin in the
samples  was  used for normalization. p values were
calculated by using Welch 2-sample t-test. *, p value <0.05;The numbers shown here are the up or down regulated proteins selec
p value <0.05. Nuc, nucleus; Cyto-s, cytosol; Cyto-p, cytoplasm; Mito,
eight biological replicates (see supplementary Table S1) were
calculated  and analyzed. The majority of the detected pro-
teins  were  cytoplasmic, including 241 mitochondrial proteins
and  118 cytoskeletal proteins (Table 1). 532 nuclear proteins
were  also detected. Evidently, iTRAQ provided the detection
and  comparison of the protein levels of a large number of
proteins,  which cannot be achieved by using other proteomic
techniques, such as two-dimensional gel electrophoresis and
mass  spectrometry [12].
3.2.  iTRAQ  data  analysis  shows  that  the  levels  of  a
number of  detected  proteins  were  consistently  changed  in
lung cancer  cells
We  combined eight sets of data from iTRAQ analysis (see
supplementary Table S1) and identiﬁed proteins whose levels
were  consistently up- or downregulated in cancer cells using
fold  changes (see Section 2). Complete lists of up- or down-
regulated proteins and their ratios in cancer vs. normal cells
are  shown in supplementary Tables S2 and S3. Then, we cal-
culated  p values for the detected proteins (see Section 2 and
supplementary Table S1). We  further narrowed down upregu-
lated  and downregulated proteins by selecting only those with
p  values <0.05. Table 1 shows the data from both fold changes
and  those with p value cutoff. 183 proteins (53 with p val-
ues  <0.05) were  consistently upregulated by at least 1.3-fold,
while  275 proteins (86 with p values <0.05) were consistently
downregulated by at least 1.3-fold in cancer cells (with ratio of
cancer  vs. normal less than 0.76).
Furthermore, we  decided to conﬁrm the detected changes
by  using the conventional Western blotting (Fig. 1A–C). To
avoid  bias, we  selected those with mean and median ranging
from  3- to 6-fold randomly. Fig. 1 shows that the upregulated
protein, nicotinamide phosphoribosyltransferase (NAMPT, see
supplementary  Table S2) was  indeed upregulated (Fig. 1A),
while  the two downregulated proteins (see supplementary
Table S3), transgelin (TAGLN, Fig. 1A) and utrophin (UTRN,
Fig.  1B), were  downregulated. The fold changes detected by
Western  blotting are largely consistent with the changes
detected by iTRAQ. Ponceau staining showed that the total
proteins  loaded for normal and cancer cells were very similar;
the  variation was  within 10% (data not shown). Furthermore,
iTRAQ can detect only proteins with relatively high levels.
Thus,  many  signaling proteins, such as cell surface receptor
EphA2,  which plays critical roles in cancer metastasis and
is  upregulated in about half of NSCLC tumor tissues [13,14],
cannot  be detected by iTRAQ. Compared to structural pro-
teins,  such as actin cytoskeletal proteins, signaling proteins
are  expressed at lower levels. However, by using Western blot-
ting, we  found that the Eph receptor, EphA2, was  upregulated
approximately 17-fold in cancer cells (Fig. 1C). The levels of**,  p value <0.005.
both total and phosphorylated (ligand activated) EphA2 pro-
teins  were  upregulated approximately 8-fold in cancer cells.
This  is consistent with previous studies showing that EphA2
is  highly upregulated in metastatic cancers [15].We  performed Gene Ontology (GO) analysis to analyze the
up-  and downregulated proteins. Although applying p val-
ues  substantially decreased the number of proteins changed
e u  p a o p e n p r o t e o m i c s 3 ( 2 0 1 4 ) 1–12 5
Table 2 – A list of actin cytoskeletal proteins downregulated in NSCLC cells.
Protein ID Gene symbol Description Fold p-Value
NP 001605 ACTG1 Actin, cytoplasmic 2 0.3 2.39E−03
NP 001005386 ACTR2 Actin-related protein 2 0.6 1.67E−02
NP 005712 ACTR3 Actin-related protein 3 0.3 3.18E−06
NP 653080 AKAP12 A-kinase anchor protein 12 0.4 7.45E−11
NP 001002858 ANXA2 Annexin A2 isoform 1 0.1 3.60E−68
NP 005709 ARPC4  Actin-related protein 2/3 complex subunit 4 0.5 4.10E−02
NP 004333 CALD1 Caldesmon isoform 2 0.1 7.12E−10
NP 001894 CTNNA1 Catenin alpha-1 0.4 1.67E−02
NP 060293 DUSP23 Dual speciﬁcity protein phosphatase 23 0.1 3.09E−03
NP 001104026 FLNA Filamin-A isoform 2 0.2 4.46E−29
NP 001157791 FLNB Filamin-B isoform 4 0.6 5.50E−03
NP 001157789 FLNB Filamin-B isoform 1 0.5 4.33E−02
NP 001531 HSPB1 Heat shock protein beta-1 0.1 4.17E−09
NP 003861 IQGAP1 Ras GTPase-activating-like protein 0.5 1.54E−03
NP 000413 KRT17 Keratin, type I cytoskeletal 17 0.1 2.67E−05
NP 005547 KRT7 Keratin, type II cytoskeletal 7 0.3 3.22E−08
NP 002435 MSN Moesin 0.6 1.36E−04
NP 001243024 MYH10 Myosin-10 isoform 3 0.1 1.12E−02
NP 002464 MYH9 Myosin-9 0.2 2.04E−55
NP 066299 MYL6 Myosin light polypeptide 6 0.4 1.06E−07
NP 006088 MYL9 Myosin regulatory light polypeptide 9 0.1 1.57E−02
NP 001074419 MYO1C Myosin-Ic 0.2 1.84E−05
NP 006087 NDRG1  Protein NDRG1 0.1 4.40E−04
NP 976227 PDLIM7 PDZ and LIM domain protein 7 0.2 1.90E−04
NP 005013 PFN1 Proﬁlin-1 0.6 2.04E−03
NP 004395 Sept2 Septin 2 0.6 2.98E−03
NP 003177 TAGLN Transgelin 0.2 4.10E−03
NP 003555 TAGLN2 Transgelin-2 0.1 3.60E−16
NP 006280 TLN1 Talin-1 0.4 1.88E−11
NP 066932 TMSB4X Thymosin beta-4 0.3 1.10E−02
NP 001018006 TPM1 Tropomyosin alpha-1 chain 0.6 2.79E−03
NP 705935 TPM3 Tropomyosin alpha-3 chain 0.7 2.22E−02
NP 001138632 TPM4 Tropomyosin alpha-4 chain 0.3 1.52E−06
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NP 009055 UTRN Utrophin 
NP 003452 ZYX Zyxin 
n NSCLC cells, the trends of changes and the main con-
lusions  remained remarkably unchanged (see Table 1 and
ata  described below). For example, 124 (72 + 52; 17 + 17 with
 value cutoff) out of 532 detected nuclear proteins were
hanged, while 52 (18 + 34; 5 + 7 with p value cutoff) out of 241
etected  mitochondrial proteins were  changed. The sensitiv-
ty  of iTRAQ, not experimental artifacts, is likely responsible
or  the lower number of proteins with statistically signiﬁ-
ant  p values. Thus, many  detected changes may  be valid,
ven  though the p values are too high. The most striking
hange is that many  (82 or 37 out of 118) of the detected pro-
eins  with functions in the formation and regulation of actin
ytoskeleton were  changed. Furthermore, among those actin
ytoskeletal  proteins changed in cancer cells, all but one of
hese  proteins were  downregulated in cancer cells (see column
Act”  Table 1).
.3.  Network  analysis  reveals  characteristic  changes
nderlying the  transformation  of  lung  cancer  cells
he most prominent change in lung cancer cells identi-
ed  by iTRAQ and GO analysis is the downregulation of
n  overwhelming majority of detected proteins involved in
he  function and regulation of the actin cytoskeleton (see
ables  1 and 2). These proteins (Table 2) play important roleshain 0.3 9.18E−09
0.1 3.09E−02
0.5 5.26E−03
in  the formation of actin stress ﬁbers and in cell adhesion
and  motility [16–19]. These proteins form a complex net-
work  (Fig. 2) connecting the functions of actin cytoskeleton,
adhesion and extracellular matrix. (For complete information
and  for comparison, changed proteins selected only by fold
changes  and those by both fold changes and p values are high-
lighted  differently in the networks.) The downregulation of
these  proteins likely leads to the changes in actin cytoskele-
ton,  cell–cell adhesion and cell motility accompanying cancer
cell  transformation.
Another important class of proteins that were  changed in
cancer  cells are the nuclear proteins. We found that 72 (17 with
p  value cutoff) nuclear proteins were  upregulated (Table 3),
while  52 (17 with p value cutoff) were downregulated in can-
cer  cells (Table 4). These nuclear proteins can interact with
each  other, and they form a very interconnected network (see
Fig.  3). The result suggests that the coordinated changes in this
network of nuclear proteins may  lead to further downstream
changes underlying cancer cell transformation. Indeed, many
of  these nuclear proteins have regulatory functions, and can
affect  proteins in other cellular compartments. For exam-
ple,  Fig. 4 shows that many  of the changed nuclear proteins
are  directly connected to those changed proteins in actin
cytoskeleton. Very likely, the changes in these nuclear pro-
teins  contribute, at least in part, to the changes in these
6  e u  p a o p e n p r o t e o m i c s 3 ( 2 0 1 4 ) 1–12
Fig. 2 – Graphical representation of protein-protein interaction networks for downregulated actin cytoskeletal proteins. The
network was  constructed using the tools and edge data available on the Genemania website. Node attribute assignment (GO
terms and Expression) was  performed in Cytoscape along with network arrangement. Final visuals were  performed in
CANVAS. Blue and light blue nodes represent proteins that are down regulated in cancer. Dark blue ones are selected based
on both fold changes and p values, while light blue ones are selected based only on fold changes. Gray nodes represent
unchanged proteins present in the network. Where possible nodes are positioned into sub-cellular features based on Gene
Ontology terms. Lines represent an association of the protein to an interaction, a particular complex or functional GO term.
The proteins shown in light red ovals are those involved in the formation of dorsal and ventral stress ﬁbers. Proteins shown
in the light green circle are those involved in focal adhesions. (For interpretation of the references to color in this ﬁgure
e.)legend, the reader is referred to the web  version of the articl
actin cytoskeletal proteins. For example, the changes in NCL
(nucleolin)  and PPP1CB may  contribute to changes in the
expression  of actin cytoskeletal proteins, such as MYH9 and
MYL9  (see Fig. 4).Compared  to nuclear proteins, the number of changed
mitochondrial proteins is small (Table 1). Nonetheless, it is
interesting  to note that two proteins relating to heme syn-
thesis  and function [20], UQCRB and cytochrome c1 (Table 5),
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Table 3 – A list of nuclear proteins upregulated in NSCLC cells.
Protein ID Gene symbol Description Fold p-Value
NP 001632 APEX1 d-(apurinic or apyrimidinic site) lyase 2.6 7.38E−05
NP 005785 DHRS2 Dehydrogese/reductase SDR family member 2 3.2 2.23E−05
NP 002005 FKBP4 Peptidyl-prolyl cis–trans isomerase FKBP4 2.2 1.90E−03
NP 005508 HMGN2 Non-histone chromosomal protein HMG-17 3.5 4.27E−02
NP 006382 IPO7 Importin-7 3 2.40E−06
NP 573566 LRPPRC Leucine-rich PPR motif-containing protein 3.9 4.71E−14
NP 004528 NAP1L1 Nucleosome assembly protein 1-like 1 4.2 6.31E−03
NP 055680 NCAPD2 Non-SMC condensin I complex, subunit D2 87.9 8.12E−05
NP 005372 NCL Nucleolin 2.8 1.81E−13
NP 001018146 NME1-NME2 NME1–NME2 protein 3.3 3.76E−11
NP 002559 PABPC1 Polyadenylate-binding protein 1 1.7 4.22E−03
NP 066953 PPIA Peptidyl-prolyl cis–trans isomerase A 1.8 1.40E−02
NP 006436 PRPF8 Pre-mR-processing-splicing factor 8 9.7 2.20E−02
NP 116559 RECQL ATP-dependent D helicase Q1 1.9 1.43E−02
NP 006704 SUB1 Activated RNAPII transcriptional coactivator p15 4.3 6.43E−09
NP 001153147 SYNCRIP Heterogeneous nuclear ribonucleoprotein Q 1.9 4.44E−04
NP 001460 XRCC6 X-ray repair cross-complementing protein 6 1.5 3.58E−03
Table 4 – A list of nuclear proteins downregulated in NSCLC cells.
Protein ID Gene symbol Description Fold p-Value
NP 001611 AHNAK Neuroblast differentiation-associated protein AHK 0.3 1.79E−39
NP 612429 AHNAK2 Protein AHNAK2 0.2 4.41E−02
NP 653080 AKAP12 A-kinase anchor protein 12 0.4 7.45E−11
NP 060293 DUSP23 Dual speciﬁcity protein phosphatase 23 0.1 3.09E−03
NP 001387 DYRK1A Dual speciﬁcity tyrosine-phosphorylation-regulated kinase 1A 0.2 4.33E−02
NP 055416 EHD2 EH domain-containing protein 2 0.2 2.08E−10
NP 001104026 FLNA Filamin-A 0.2 4.46E−29
NP 057371 HP1BP3 Heterochromatin protein 1-binding protein 3 0.3 3.14E−03
NP 001531 HSPB1 Heat shock protein beta-1 0.1 4.17E−09
NP 003861 IQGAP1 Ras GTPase-activating-like protein 0.5 1.54E−03
NP 015556 Kif22 Kinesin family member 22 0.1 1.39E−02
NP 002259 KPNA4 Importin subunit alpha-4 0.3 3.04E−02
NP 059447 MVP Major vault protein 0.5 1.77E−04
NP 001074419 MYO1C Myosin-Ic isoform b 0.2 1.84E−05
NP 006087 NDRG1 Protein NDRG1 0.1 4.40E−04
NP 002700 PPP1CB S/T-protein phosphatase PP1-beta catalytic subunit 0.6 4.19E−02
NP 036364 PTRF Polymerase I and transcript release factor 0.3 1.06E−06
Table 5 – A list of mitochondrial proteins upregulated in NSCLC cells.
Protein ID Gene symbol Description Fold p-Value
NP 001203 C1QBP Complement 1 Q subcomponent-binding protein 1.5 3.27E−02
NP 001907 CYC1 Cytochrome c1, heme protein 4.3 3.61E−02
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re upregulated, although only 5 mitochondrial proteins were
etected  to be upregulated (with p values <0.05) in cancer cells.
his  is consistent with our results from another recent study
howing  that enhanced heme function promotes lung cancer
rogression  [21].
.4.  Immunoﬂuorescence  microscopy  conﬁrms  that  the
ctin  cytoskeletal  structure  is  permanently  altered  in  lung
ancer  cells
he iTRAQ results showing the systematic downregulation of
any  proteins involved in actin cytoskeleton lead us to pos-
ulate  that actin cytoskeletal structure is dramatically altered
n  NSCLC cells. To test this idea, we performed immuno-
uorescence microscopy to compare the formation of actinein 3.3 5.19E−16
-containing protein 3.9 4.71E−14
plex subunit 7 6.1 1.68E−02
cytoskeletal  structures in the normal HBEC30KT cells and two
NSCLC cell lines HCC4017 and A549 (see Fig. 5A and B). We
used  phalloidin staining to examine and compare stress ﬁber
formation  in normal and cancer lung cells. We  also stained
vinculin in order to examine focal adhesions in the cells
[11,22].  Fig. 5 shows the result of microscopic analysis. Clearly,
stress  ﬁber formation was  very strong and prominent in the
normal  lung cells, as expected (see the prominent thick red
ﬁbers  in the HBEC panels of Fig. 5A and B). In the lung cancer
cells,  however, stress ﬁber formation was  substantially weak-
ened  (see the weak and narrow red ﬁbers in the panels HCC
and  A549). Likewise, stronger and more  prominent adhesions
were  formed in the normal cells, compared to the cancer cells
(see  the prominent and thick green bands in the panel HBEC in
Fig.  5A and B; in panels HCC and A549, only green spots were
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Fig. 3 – Graphical representation of protein–protein interaction networks for up- and downregulated nuclear proteins. The
network was  constructed in the same manner as Fig. 2. Red and light red nodes represent proteins upregulated in cancer,
selected based on both fold changes and p values and on fold changes, respectively. Blue and light blue ones represent
proteins downregulated in cancer, selected based on both fold changes and p values and on fold changes, respectively. Gray
nodes represent unchanged proteins present in the network. Lines represent an association of the protein to an interaction,
a particular complex or functional GO term. (For interpretation of the references to color in this ﬁgure legend, the reader is
referred to the web  version of the article.)
detected, showing decreased formation of focal adhesions).
These  results conﬁrmed the results from the iTRAQ studies
and  showed that the formation of actin cytoskeleton and focal
adhesions  is permanently altered during the transformation
of  normal lung cells to NSCLC cells.
4.  Discussion
iTRAQ mass spectrometry analysis provides a systematic way
to identify the changes in proteins in lung cancer vs. nor-
mal  cells, in the absence of any preconceived limitation and
selection.  This approach should identify the most prominent
protein  changes in cancer cells in an unbiased manner. Using
iTRAQ,  we  detected 1584 proteins in the normal HBEC30KTand  cancer HCC4017 lung cells. Among them, the levels of
183  (53 with p value cutoff) proteins were signiﬁcantly upregu-
lated,  while the levels of 275 (86 with p value cutoff) proteins
were  downregulated (Table 1). The most striking difference
occurred in actin cytoskeleton, where 81 proteins (∼3/4 of the
detected  proteins; 36 with p value cutoff) were downregulated,
while only 1 was  upregulated, among the 118 detected actin
cytoskeletal proteins. The main conclusions from using the
information  from proteins selected by using only fold changes
and  from using both fold changes and p value cutoff are largely
the  same. Thus, the information gained from the analysis of
the  larger number of changed proteins may  also be biologically
relevant. Thus, we included all changed proteins in Figs. 2–4.
The  downregulated actin cytoskeletal proteins include
mainly those involved in the formation of stress ﬁbers
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Fig. 4 – Graphical representation of interaction networks for altered nuclear proteins and downregulated actin cytoskeletal
proteins. The network was constructed using tools and edge data provided by the Pathway Studios program version 7.
Cytoscape was  used for network arrangement and CANVAS for ﬁnal visuals. Red and blue arrows represent positive and
negative regulatory edge interaction, respectively. Red and light red nodes represent altered nuclear proteins, selected based
on both fold changes and p values and on fold changes, respectively. Blue and light blue nodes represent downregulated
actin cytoskeletal proteins, selected based on both fold changes and p values and on fold changes, respectively. (For
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both dorsal and ventral), focal adhesions, and cortical actin
ytoskeleton (Fig. 2) [16–19]. These proteins include ACTR2 and
CTR3,  which are components of the Arp2/3 complex (see
able  2 and Fig. 2). The Arp2/3 complex stimulates the forma-
ion  of new actin ﬁlaments at the leading edge of motile cells,
roduces  branches on the sides of existing ﬁlaments, and is
mportant  for cell motility [23,24]. Filamin A and B, which are
mportant  for regulating the formation of actin cytoskeleton
etwork [25,26], were  downregulated. The downregulated pro-
eins also include myosin and tropomyosin chains, inlcuding
YH9,  MYH10, MYL6, MYL9, MYO1C, TPM1, TPM3, TPM4 (see
ig.  2 and Table 2), which have important functions in cell reader is referred to the web  version of the article.)
motility  and its regulation [27,28]. Sept2 and other septins,
which  are key components of cytoskeleton [29], were  down-
regulated.  Many of these proteins are critical for stress ﬁber
formation  (Fig. 2) [16,30]. Furthermore, proteins involved in the
formation  of focal adhesions [17,19,22,31,32], such as PFN1 and
TLN1,  were  downregulated. The downregulation of such a high
number of proteins involved in the function and regulation
of  actin cytoskeleton indicates signiﬁcant changes in actin
cytoskeleton and cell motility in lung cancer cells. Notably, this
result is also supported by previous comparative proteomic
studies of tumor and normal lung tissues. For example, in the
study  by Li et al., among only 11 identiﬁed proteins that are
10  e u  p a o p e n p r o t e o m i c
Fig. 5 – Fluorescent microscopic images of stress ﬁbers and
focal  adhesions formed in normal and cancer lung cells.
HBEC30KT, HCC4017 and A549 cells were  grown, and
F-actin  was  visualized with Alexa Fluor 568-phalloidin.
Focal adhesions were  visualized by using a monoclonal
anti-vinculin antibody, followed by detection with a
FITC-conjugated goat anti-mouse IgG antibody. B shows
enlarged  version of the boxed areas in A. The bar indicates
shows  that permanent systematic changes in a large number10  m.
decreased in tumor tissues, 3 are actin cytoskeletal proteins
[33].  In another study, it was  shown that 3 of the 16 downregu-
lated  proteins in tumor tissues are actin cytoskeletal proteins
[34].
Indeed,  the changes in actin cytoskeleton in NSCLC cells
were  readily conﬁrmed by ﬂuorescent microscopy. Fig. 5 shows
that  the formation of stress ﬁbers and focal adhesions were
substantially diminished in NSCLC HCC4017 and A549 cells,
compared  to the normal cells. Changes in actin cytoskele-
ton  were  found to be critical for malignant tumor formation
and  for promoting the function of oncogenes in tumor pro-
gression  more  than two decades ago [35]. More  recent studies
have  demonstrated the importance of regulation of actin
cytoskeleton in cancer cell migration and invasion. Stabiliz-
ing  actin cytoskeleton is critical for stopping invading cancer s 3 ( 2 0 1 4 ) 1–12
cells  and arresting cancer progression [36–39]. Here, our data
showed  that a systematic and preferential downregulation of
actin  cytoskeletal proteins diminshes the formation of both
stress  ﬁbers and focal adhesions, leading to the transforma-
tion  of normal lung cells to NSCLC cells. While many  potential
mechanisms can cause changes in actin cytoskeleton [17,18],
our  data show that the systematic downregulation of many
actin  cytoskeletal proteins is a key factor in the progres-
sion  of NSCLC cells. Perhaps this mechanism to change actin
cytoskeleton  also operates in other kinds of cancer cells.
Additionally, it is worth noting that NAMPT, TAGLN and
EphA2,  whose changes were conﬁrmed by Western blotting
here,  have been investigated peviously regarding their roles
in  lung cancer. NAMPT, nicotinamide phosphoribosyltrans-
ferase precursor, is known to be a therapeutic target for lung
cancer  and inﬂammation-related disorders [40,41]. Hence, its
upregulation in NSCLC cells detected here is consistent with
its  known role in cancer. A previous study identiﬁed NAMPT
as  one of the genes whose transcript levels are downregu-
lated in lung cancer tissues [42]. There are two reasons that
can  account for the discrepancy with our results. First, we
detected  proteins, not mRNA.  Second, our data are obtained
using  homogenous cells, while the previous analyzed data
used  cancer tissues, which contains a combination of dif-
ferent  cell types [42]. Our data showed that the levels of
both  TAGLN (transgelin) and TAGLN2 proteins were  downreg-
ulated  in NSCLC cells. A previous study has shown that the
upregulation of TAGLN expression exerts anti-tumor growth
and  anti-metastasis effects, whereas its levels are inversely
correlated with colorectal cancer metastasis [43]. Another
study  found that TAGLN is upregulated in the tumor-induced
reactive myoﬁbroblastic stromal tissue compartment, while
TAGLN2  is upregulated in the neoplastic glandular compart-
ment  [44]. These and our results suggest that TAGLN plays an
important role in cancer progression.
Further, our Western blotting analysis showed that the
levels  of both total and ligand-activated (detected by using
antibodies to phosphorylated protein) EphA2 proteins were
strongly  increased in NSCLC cells (Fig. 1C). Eph receptors are
shown  to play a wide array of roles in cell adhesion and cell
movement, as well as in cancer progression [13,15,45–47]. Par-
ticularly,  the EphA2 receptor has been found to be widely
overexpressed in many  cancer types [48–50]. The overexpress-
ion  of EphA2 in NSCLC cells likely contributes to the changes
in  actin cytoskeleton and adhesions [47].
It is worth noting that a good number of nuclear proteins
were up- or downregulated in NSCLC cells (Tables 3 and 4
and  Fig. 3). These proteins are involved in diverse func-
tions  in the nucleus, and many  interact directly with each
other  (Fig. 3). Interestingly, many  of these nuclear proteins
also  directly interact with the downregulated proteins in
actin  cytoskeleton (Fig. 4). The changes in the nucleus and
actin  cytoskeleton may  synergize with each other and fur-
ther  promote the transformation of normal cells to cancer
cells.  This comparative proteomic study of cancer vs. nor-
mal  cells employing iTRAQ technology and network analysisof  cellular proteins accompany the progression of lung cancer
cells,  and that iTRAQ is a powerful technique to identify such
changes.
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.  Conclusions
ung cancer cells exhibit characteristic changes in proteins,
hen  compared to the normal lung epithelial cells. The
ost  dramatic change is the systemic downregulation of
any  proteins with functions in actin cytoskeleton and adhe-
ion.  This downregulation leads to substantial changes in
ctin  cytoskeletal structure, thereby altering cell motility and
igration  and leading to the progression of lung cancer cells.
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